What is Nu-Med Plus's earnings per share (EPS)?

Nu-Med Plus (NUMD) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Nu-Med Plus Financials

NUMD

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Nu-Med Plus (NUMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NUMD FY2025 2026-05-14

Nu-Med Plus is being carried by shrinking liquidity while near-term obligations keep expanding faster than resources.

Between FY2022 and FY2025, cash fell from $73K to $661 while total liabilities climbed from $143K to $279K; that combination says more than the missing revenue lines because the business appears to be absorbing ongoing costs by letting obligations accumulate as liquid resources disappear. Even FY2024 operating cash flow improving to -$4K did not arrest the slide, with assets at just $8K in FY2025 and current coverage down to 0.03x.

The company’s liquidity pressure is immediate, not parked in long-term financing: in FY2025, current liabilities matched total liabilities at $279K, against only $8K of current assets. That leaves very little balance-sheet cushion if any obligation must be settled in cash.

Reported overhead is small in absolute dollars, but large relative to available cash: FY2025 SG&A was $23K versus just $661 of cash. With shares outstanding essentially flat at 83.5M since FY2023, the reported balance-sheet weakening was not accompanied by a visible expansion in the common-share base.

Financial Health Signals

Financial Profile 16/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Nu-Med Plus's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Nu-Med Plus carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Nu-Med Plus's current ratio of 0.03 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$0.00

Nu-Med Plus earned $0.00 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$661

YoY-72.1%

5Y CAGR-67.7%

10Y CAGR-31.9%

Nu-Med Plus held $661 in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

84M

YoY+0.0%

5Y CAGR+10.7%

10Y CAGR+8.7%

Nu-Med Plus had 84M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

NUMD Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$23K-32.7%	$34K+24.6%	$28K+3.7%	$27K-17.7%	$32K-44.6%	$58K
Operating Income	N/A	N/A	N/A	-$182K	N/A	-$2.0M
Interest Expense	$7K+44.1%	$5K+0.3%	$5K+400.0%	$1K	N/A	$14K
Income Tax	N/A	N/A	N/A	N/A	N/A	$0
Net Income	N/A	N/A	N/A	-$130K	N/A	-$2.0M
EPS (Diluted)	$0.00	$0.00	$0.00	$0.00+100.0%	$-0.01+75.0%	$-0.04

Metric	Q1'26	Q4'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$0	N/A	$0	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$5K	N/A	$6K	N/A	$9K	N/A	$6K	N/A
Operating Income	-$13K	N/A	-$19K	N/A	-$17K	N/A	-$21K	N/A
Interest Expense	$3K	N/A	$1K	N/A	$1K	N/A	$1K	N/A
Income Tax	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$16K	N/A	-$20K	N/A	-$19K-8.0%	-$17K+20.8%	-$22K	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	$0.00	N/A	$0.00	N/A

NUMD Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$8K-15.6%	$9K-30.3%	$13K-83.1%	$80K+258.9%	$22K-96.0%	$557K
Current Assets	$8K-15.6%	$9K-30.3%	$13K-83.1%	$80K+581.3%	$12K-97.8%	$538K
Cash & Equivalents	$661-72.1%	$2K-65.1%	$7K-90.7%	$73K+526.9%	$12K-93.8%	$189K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$279K+24.4%	$224K+40.1%	$160K+12.4%	$143K-7.7%	$155K+72.8%	$89K
Current Liabilities	$279K+24.4%	$224K+40.1%	$160K+12.4%	$143K-7.7%	$155K+93.0%	$80K
Long-Term Debt	$0	N/A	N/A	N/A	N/A	N/A
Total Equity	-$271K-26.1%	-$215K-46.6%	-$147K-132.8%	-$63K+52.4%	-$132K-128.3%	$468K
Retained Earnings	-$9.9M-0.6%	-$9.9M-0.7%	-$9.8M-1.3%	-$9.7M-1.4%	-$9.6M-9.5%	-$8.7M

Metric	Q1'26	Q4'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$7K-9.2%	$8K	N/A	$9K+37.0%	$7K	N/A	$9K-33.0%	$13K
Current Assets	$7K-9.2%	$8K	N/A	$9K+37.0%	$7K	N/A	$9K-33.0%	$13K
Cash & Equivalents	$4K+548.1%	$661-72.1%	$2K0.0%	$2K-41.3%	$4K	N/A	$6K-6.6%	$7K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$294K+5.4%	$279K	N/A	$224K+6.2%	$211K	N/A	$178K+10.9%	$160K
Current Liabilities	$294K+5.4%	$279K	N/A	$224K+6.2%	$211K	N/A	$178K+10.9%	$160K
Long-Term Debt	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$287K-5.9%	-$271K-15.4%	-$235K-9.3%	-$215K-5.2%	-$205K-10.0%	-$186K-10.3%	-$169K-14.9%	-$147K
Retained Earnings	-$10.0M-0.2%	-$9.9M	N/A	-$9.9M-0.1%	-$9.9M	N/A	-$9.8M-0.2%	-$9.8M

NUMD Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	N/A	-$4K+93.3%	-$66K-72.5%	-$38K	N/A	-$415K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$0
Financing Cash Flow	N/A	N/A	N/A	$100K+233.3%	$30K-95.0%	$596K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$6K	N/A	$0+100.0%	-$2K	N/A	N/A	-$450+89.5%	-$4K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0	N/A	$0	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$10K	N/A	$0	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NUMD Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	-429.5%
Return on Assets	N/A	N/A	N/A	-163.6%	N/A	-360.6%
Current Ratio	0.03-0.0	0.04-0.0	0.08-0.5	0.56+0.5	0.08-6.6	6.71
Debt-to-Equity	0.00+1.0	-1.04+0.0	-1.09+1.2	-2.26-1.1	-1.17-1.4	0.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-221.0%	N/A	N/A	N/A	-273.0%	N/A	-242.1%	N/A
Current Ratio	0.020.0	0.03	N/A	0.040.0	0.03	N/A	0.05-0.0	0.08
Debt-to-Equity	0.000.0	0.00	N/A	-1.04-0.0	-1.03	N/A	-1.05+0.0	-1.09
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$271K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

How much debt does Nu-Med Plus have?

As of fiscal year 2025, Nu-Med Plus (NUMD) had $661 in cash and equivalents against $0 in long-term debt.

What are Nu-Med Plus's total assets?

Nu-Med Plus (NUMD) had $8K in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Nu-Med Plus have outstanding?

Nu-Med Plus (NUMD) had 84M shares outstanding as of fiscal year 2025.

What is Nu-Med Plus's current ratio?

Nu-Med Plus (NUMD) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Nu-Med Plus's debt-to-equity ratio?

Nu-Med Plus (NUMD) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is Nu-Med Plus's debt-to-equity ratio negative or unusual?

Nu-Med Plus (NUMD) has negative shareholder equity of -$271K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Nu-Med Plus?

Nu-Med Plus (NUMD) scores 16 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.